These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 8391304)
1. The control of acute cisplatin-induced emesis--a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Granisetron Study Group. Chevallier B Br J Cancer; 1993 Jul; 68(1):176-80. PubMed ID: 8391304 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group. Chevallier B Eur J Cancer; 1990; 26 Suppl 1():S33-6. PubMed ID: 2169784 [TBL] [Abstract][Full Text] [Related]
3. Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group. Heron JF; Goedhals L; Jordaan JP; Cunningham J; Cedar E Ann Oncol; 1994 Sep; 5(7):579-4. PubMed ID: 7993831 [TBL] [Abstract][Full Text] [Related]
4. A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic-induced emesis. The Granisetron Study Group. Marty M Eur J Cancer; 1992; 28A Suppl 1():S12-6. PubMed ID: 1320913 [TBL] [Abstract][Full Text] [Related]
5. Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial. Gebbia V; Testa A; Valenza R; Cannata G; Tirrito ML; Gebbia N Cancer; 1995 Nov; 76(10):1821-8. PubMed ID: 8625054 [TBL] [Abstract][Full Text] [Related]
6. The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. The Granisetron Study Group. J Cancer Res Clin Oncol; 1993; 119(9):555-9. PubMed ID: 8392077 [TBL] [Abstract][Full Text] [Related]
7. A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial. Warr D; Wilan A; Venner P; Pater J; Kaizer L; Laberge F; Latreille J; Stewart D; O'Connell G; Osoba D Eur J Cancer; 1992; 29A(1):33-6. PubMed ID: 1332737 [TBL] [Abstract][Full Text] [Related]
8. Fractionated chemotherapy--granisetron or conventional antiemetics? The Granisetron Study Group. Diehl V Eur J Cancer; 1992; 28A Suppl 1():S21-8. PubMed ID: 1320916 [TBL] [Abstract][Full Text] [Related]
9. Ondansetron plus dexamethasone compared to the 'standard' metoclopramide combination. Roila F Oncology; 1993; 50(3):163-7. PubMed ID: 8459986 [TBL] [Abstract][Full Text] [Related]
10. Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam. Cunningham D; Dicato M; Verweij J; Crombez R; de Mulder P; du Bois A; Stewart A; Smyth J; Selby P; van Straelen D; Parideans R; McQuade B; McRae J Ann Oncol; 1996 Mar; 7(3):277-82. PubMed ID: 8740792 [TBL] [Abstract][Full Text] [Related]
11. Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis. Warr D; Willan A; Fine S; Wilson K; Davis A; Erlichman C; Rusthoven J; Lofters W; Osoba D; Laberge F J Natl Cancer Inst; 1991 Aug; 83(16):1169-73. PubMed ID: 1653363 [TBL] [Abstract][Full Text] [Related]
12. A randomized cross-over study of high-dose metoclopramide plus dexamethasone versus granisetron plus dexamethasone in patients receiving chemotherapy with high-dose cisplatin. Ohmatsu H; Eguchi K; Shinkai T; Tamura T; Ohe Y; Nisio M; Kunikane H; Arioka H; Karato A; Nakashima H Jpn J Cancer Res; 1994 Nov; 85(11):1151-8. PubMed ID: 7829401 [TBL] [Abstract][Full Text] [Related]
14. Role of ondansetron plus dexamethasone in fractionated chemotherapy. Räth U; Upadhyaya BK; Arechavala E; Böckmann H; Dearnaley D; Droz JP; Fosså SD; Henriksson R; Aulitzky WE; Jones WG Oncology; 1993; 50(3):168-72. PubMed ID: 8459987 [TBL] [Abstract][Full Text] [Related]
15. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415 [TBL] [Abstract][Full Text] [Related]
16. Comparison of intravenous granisetron with metoclopramide plus dexamethasone in the prevention of nausea and vomiting associated with emetogenic cytotoxic chemotherapy. Chang CS; Chen LT; Huang SM; Liu TC; Lin SF; Chen TP; Wei TC Kaohsiung J Med Sci; 1997 Feb; 13(2):97-102. PubMed ID: 9099048 [TBL] [Abstract][Full Text] [Related]
17. Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis. Bhatia A; Tripathi KD; Sharma M Indian J Med Res; 2004 Sep; 120(3):183-93. PubMed ID: 15489556 [TBL] [Abstract][Full Text] [Related]
18. Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic. Plosker GL; Goa KL Drugs; 1991 Nov; 42(5):805-24. PubMed ID: 1723376 [TBL] [Abstract][Full Text] [Related]
19. A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Aapro MS; Thuerlimann B; Sessa C; De Pree C; Bernhard J; Maibach R; Ann Oncol; 2003 Feb; 14(2):291-7. PubMed ID: 12562658 [TBL] [Abstract][Full Text] [Related]
20. A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group. Marty M Eur J Cancer; 1990; 26 Suppl 1():S28-32. PubMed ID: 2169783 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]